DOJ Expands Antitrust Probe to Include Claritev

The U.S. Department of Justice (DOJ) has widened its antitrust investigation into the healthcare sector to include Claritev, a health claims management firm, according to sources familiar with the matter. This expansion comes on the heels of ongoing probes into UnitedHealth Group (UNH) and CVS Health (CVS).

Details of the Action

The DOJ has not disclosed the exact scope of the expanded probe, but sources indicate it focuses on Claritev's claims management practices and its relationships with insurers and healthcare providers. The investigation is believed to examine potential anticompetitive conduct or collusion.

Company's Response

Claritev issued a statement affirming its full cooperation with the investigation but provided no further details. The company said, "We are committed to transparency and compliance with the law, and we will continue to work with regulators."

Precedents and Context

This expansion follows months of similar investigations into UnitedHealth and CVS regarding their pharmacy and managed care practices. Those probes have not yet yielded public outcomes. Observers suggest the DOJ is seeking to uncover a broader network of anticompetitive practices in the healthcare industry.

Potential Financial Impact

The potential financial impact on Claritev or other companies remains unclear. However, prolonged investigations can lead to significant fines, settlements, or mandated changes in business practices. UnitedHealth and CVS have not commented on the latest development.